421 related articles for article (PubMed ID: 17889125)
1. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.
Mastrobuoni S; Ubilla M; Cordero A; Herreros J; Rabago G
Transplant Proc; 2007 Sep; 39(7):2163-6. PubMed ID: 17889125
[TBL] [Abstract][Full Text] [Related]
2. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.
Becker T; Foltys D; Bilbao I; D'Amico D; Colledan M; Bernardos A; Beckebaum S; Isoniemi H; Pirenne J; Jaray J;
Transplantation; 2008 Dec; 86(12):1689-94. PubMed ID: 19104406
[TBL] [Abstract][Full Text] [Related]
3. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O
Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
5. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.
Schuller S; Wiederkehr JC; Coelho-Lemos IM; Avilla SG; Schultz C
Transplant Proc; 2005 Mar; 37(2):1151-2. PubMed ID: 15848653
[TBL] [Abstract][Full Text] [Related]
6. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
7. Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation.
Joyal D; Cantarovich M; Cecere R; Giannetti N
Clin Transplant; 2004 Oct; 18(5):493-6. PubMed ID: 15344949
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.
Rostaing L; Cantarovich D; Mourad G; Budde K; Rigotti P; Mariat C; Margreiter R; Capdevilla L; Lang P; Vialtel P; Ortuño-Mirete J; Charpentier B; Legendre C; Sanchez-Plumed J; Oppenheimer F; Kessler M;
Transplantation; 2005 Apr; 79(7):807-14. PubMed ID: 15818323
[TBL] [Abstract][Full Text] [Related]
9. Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients.
Figueras J; Bernardos A; Prieto M; Gómez M; Rimola A; Ortiz de Urbina J; Cuervas-Mons V; de la Mata M; Dominguez-Granados R
Transplant Proc; 2002 Aug; 34(5):1511-3. PubMed ID: 12176461
[No Abstract] [Full Text] [Related]
10. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
[TBL] [Abstract][Full Text] [Related]
11. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
Sánchez-Fructuoso AI; Prats D; Marques M; Ridao N; Conesa J; García Mena M; Torrente J; Barrientos A
Transplant Proc; 2003 Aug; 35(5):1689-90. PubMed ID: 12962759
[TBL] [Abstract][Full Text] [Related]
12. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.
Kuypers DR; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
Clin Transplant; 2003 Jun; 17(3):234-41. PubMed ID: 12780674
[TBL] [Abstract][Full Text] [Related]
13. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
[TBL] [Abstract][Full Text] [Related]
14. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts.
Figueras J; Prieto M; Bernardos A; Rimola A; Suárez F; de Urbina JO; Cuervas-Mons V; Mata Mde L
Transpl Int; 2006 Aug; 19(8):641-8. PubMed ID: 16827681
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized study comparing cyclosporine versus tacrolimus combined with daclizumab, mycophenolate mofetil, and steroids in heart transplantation.
Sánchez-Lázaro IJ; Almenar L; Martínez-Dolz L; Buendía-Fuentes F; Agüero J; Navarro-Manchón J; Vicente JL; Salvador A
Clin Transplant; 2011; 25(4):606-13. PubMed ID: 20682020
[TBL] [Abstract][Full Text] [Related]
16. Daclizumab to prevent rejection after cardiac transplantation.
Hershberger RE; Starling RC; Eisen HJ; Bergh CH; Kormos RL; Love RB; Van Bakel A; Gordon RD; Popat R; Cockey L; Mamelok RD
N Engl J Med; 2005 Jun; 352(26):2705-13. PubMed ID: 15987919
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial.
Abramowicz D; Vanrenterghem Y; Squifflet JP; Kuypers D; Mourad M; Meurisse M; Wissing M
Clin Transplant; 2005 Aug; 19(4):475-82. PubMed ID: 16008591
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
Stratta RJ; Alloway RR; Hodge E; Lo A;
Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
[TBL] [Abstract][Full Text] [Related]
19. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
Bruce DS; Sollinger HW; Humar A; Sutherland DE; Light JA; Kaufman DB; Alloway RR; Lo A; Stratta RJ
Transplantation; 2001 Nov; 72(10):1637-43. PubMed ID: 11726823
[TBL] [Abstract][Full Text] [Related]
20. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
